💤🚀 ¡HISTORIC OPERATION! Apnimed seeks to go public in the U.S. to launch its sleep apnea drug 🚀💤
The biotech company Apnimed Inc., strategically backed by Japanese giant Shionogi, officially filed its Initial Public Offering (IPO) in the United States under the symbol $APMD on Nasdaq, as reported by Bloomberg.
The company plans to use the funds raised to finance FDA regulatory approval and the commercial launch of Oxnimbi (AD109), its revolutionary daily oral drug.
This experimental treatment promises to be a historic medical alternative to the uncomfortable traditional air pressure machines (CPAP). 📊
$ADA $BTC $ETH #Apnimed #OPI #IPO #Shionogi #PharmaNews